City

Shenzhen (2)

Hangzhou (1)

Rijeka (1)

Condition

NK Cell Mediated Immunity (4)

ADCC (1)

Adaptive Transfer (1)

Advanced Cancer (1)

Endometriosis (1)

Kidney Cancer (1)

NK Cell Cytokine Production (1)

Nimotuzumab (1)

Overall Status

Unknown status (3)

Completed (1)

Sign in for free

Phase

phase 1 (2)

early phase 1 (1)

Sponsor

Clinical Hospital Center Rijeka (1)

Hangzhou Cancer Hospital (1)

Shenzhen Fifth People's Hospital (1)

Shenzhen People's Hospital (1)

Collaborator

Shanghai bokang bioengineering co., LTD (1)

Intervention

autologous nk cell therapy (1)

gnrha combained with reverse addition therapy (1)

nimotuzumab (1)

nk cell adaptive transfer (1)

nk cells (1)

Study Documents

Intervention Type

biological (3)

drug (2)

Funder Type

Other (4)

Study Type

Interventional (3)

Observational (1)

nk cell mediated immunity

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Cellular Immunity and Renal Cell Cancer

Completed

NK Cell Mediated Immunity
+2 more

Rijeka, Croatia

Clinical Hospital Center Rijeka

Sep 19, 2021

NK Cell Mediated Immunity Trial in Shenzhen (NK cells)

Unknown status

NK Cell Mediated Immunity

NK cells

Shenzhen, Guangdong, China

Shenzhen Luohu Hospital

Dec 4, 2019

NK Cell Mediated Immunity, Endometriosis Trial in Shenzhen (Autologous NK cell therapy, GnRHa combained with reverse addition

Unknown status

NK Cell Mediated Immunity
Endometriosis

Autologous NK cell therapy
GnRHa combained with reverse addition therapy

Shenzhen, Guangdong, China

Shenzhen People's Hospital

May 12, 2019

Advanced Cancer, ADCC, NK Cell Mediated Immunity Trial in Hangzhou (NK Cell adaptive transfer, Nimotuzumab)

Unknown status

Advanced Cancer
+4 more

NK Cell adaptive transfer
Nimotuzumab

Hangzhou, Zhejiang, China

Hangzhou Cancer Hospital

Jun 12, 2018